Clinical Trial Update: Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral BCX4161 as prophylaxis for hereditary angioedema has completed, reporting safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• BCX4161

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Hereditary Angioedema | Phase 2 | Status: COMPLETED